ArticleOncotarget2015
CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- PHF5A promotes colorectal cancerprogression by alternative splicing of TEAD2.Molecular therapy. Nucleic acids · 2021Article
- Systems-level biomarkers identification and drug repositioning in colorectal cancer.World journal of gastrointestinal oncology · 2021Review
- A nine-gene signature to improve prognosis prediction of colon carcinoma.Cell cycle (Georgetown, Tex.) · 2021Article
- A 70-Gene Signature for Predicting Treatment Outcome in Advanced-Stage Cervical Cancer.Molecular therapy oncolytics · 2020Article
- Paeonol exerts anti‑tumor activity against colorectal cancer cells by inducing G0/G1 phase arrest and cell apoptosis via inhibiting the Wnt/β‑catenin signaling pathway.International journal of molecular medicine · 2020Article
- MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer.Nature communications · 2020Article
- Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.BioMed research international · 2020Article
- Cluster analysis on high dimensional RNA-seq data with applications to cancer research - An evaluation study.PloS one · 2019Article
- Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling.BMC genomics · 2018Article
- The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients.Biomedicines · 2018Review
- Article
- A long non-coding RNA expression signature to predict survival of patients with colon adenocarcinoma.Oncotarget · 2017Article
- A seven-gene signature predicts overall survival of patients with colorectal cancer.Oncotarget · 2017Article
- The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.Scientific reports · 2017Article
- Epigenetic Biomarkers in Colorectal Cancer.Molecular diagnosis & therapy · 2017Review
- An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.Oncotarget · 2016Article
- Article
- A 19-Gene expression signature as a predictor of survival in colorectal cancer.BMC medical genomics · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third leading cause of global cancer mortality. Recent studies have proposed several gene signatures to predict CRC prognosis, but none of those have proven reliable for predicting prognosis in clinical practice yet due to poor reproducibility and molecular heterogeneity. Here, we have established a prognostic signature of 113 probe sets (CRC-113) that include potential biomarkers and reflect the biological and clinical characteristics. Robustness and accuracy were significantly validated in external data sets from 19 centers in five countries. In multivariate analysis, CRC-113 gene signature showed a stronger prognostic value for survival and disease recurrence in CRC patients than current clinicopathological risk factors and molecular alterations. We also demonstrated that the CRC-113 gene signature reflected both genetic and epigenetic molecular heterogeneity in CRC patients. Furthermore, incorporation of the CRC-113 gene signature into a clinical context and molecular markers further refined the selection of the CRC patients who might benefit from postoperative chemotherapy. Conclusively, CRC-113 gene signature provides new possibilities for improving prognostic models and personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.